



NEWSLETTER

SEPTEMBER 2024
ISSUE 3

MAHs INVOICING PROCESS FOR 2025

In preparation for the **2025 invoicing cycle**, an OSMR General Assembly was held on September 12th.

As in the previous years, after a thorough analysis of the budget and having an overview of the MAHs which are marketing their serialized products on the Romanian market, it has been decided that the **amount of the operational fee for the NMVS remain the same as for the current year: 9,000 EUR/MAH.**

Also, the amount of the **affiliation tax remains the same: 5,000 EUR.**

Furthermore, OSMR would like to inform the Marketing Authorisation Holders (MAHs) that the **invoicing process will start on October 1st.**



The continuous effort that the MAHs are making to support the National Medicines Verification System (NMVS) is deeply appreciated.

By sustaining the operability of the system through the payment of the annual fees, *the MAHs are actively contributing to the overall safety and integrity of the pharmaceutical distribution chain, ensuring patients have access to authentic medicines.*

NMVS RELEASE - CORE 5.0 & REPORTING TOOL 5.0

OSMR is proud to announce that *Romania has once again taken the lead as the Pilot Country for the new NMVS Release: Core 5.0.*

As with previous releases, the OSMR technical team conducted extensive tests in both the testing (IQE) and the Production (PROD) environments, ensuring thus the system's robustness before its wider implementation.



NMVS Core 5.0 will introduce system and workflow optimizations, like for example:

- ❖ Performance improvements – which will allow faster response time and more efficient use of resources;
- ❖ Defects fixed – ensuring a more stable and reliable operation of the system.

Most importantly, *NMVS Core 5.0, which will be released on September 23rd will bring the New Graphical Interface*, the advantages of which were presented in our last [Newsletter](#) .



The continuous development of the NMVS is essential to staying ahead of emerging challenges and ensuring the authenticity of medicines on the Romanian market.

By being at the forefront of these system updates, we are reinforcing our commitment to patient safety and the integrity of the pharmaceutical supply chain.

